Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Mol Cancer Ther. 2011 Jan 31;10(4):679–686. doi: 10.1158/1535-7163.MCT-10-0833

Figure 3. Rapamycin decreases metastasis of Tg6/λ-MYC tumor cells into bone marrow.

Figure 3

The percentage of CD19 positive cells, sequentially gated on 7AAD-negative (live), singlet, lymphocyte, and CD19, as assessed with flow cytometry from bone marrow (left panel), spleen (middle panel), or tumor cells (right panel) obtained from the groups in Figure 2. Shown are also the percentages of CD19 positive cells in bone marrow and spleen from naïve wild type and Rag1 KO mice. The data are graphed as in Figure 1.